申请人:Eli Lilly and Company
公开号:US20220144816A1
公开(公告)日:2022-05-12
Disclosed herein are compounds of formula I:
or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.